Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia

References

• Rodgers G, Klugman K. The future of pneumococcal disease prevention. Vaccine 2011; 29:43–8; http://dx.doi.org/10.1016/j.vaccine.2011.07.047
   Google Scholar
• World Health Organization. Pneumococcal vaccines – WHO position paper 2012. Weekly Epidemiol Record 2012; 87:129-44
   PubMedGoogle Scholar
• Pneumococcal disease recent changes; [Internet]. Australian government department of health immunise australia program. 2012; [cited 2 Feb 2013]available from http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-pneumococcal
   Google Scholar
• Barry C, Krause VL, Cook HM, Menzies RI. Invasive pneumococcal disease in australia, 2007 and 2008. Commun Dis Intelligence Annu Rep 2012; 36(2):151-65.
   Google Scholar
• Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalisations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Paediatric Infect Dis J 2010; 29(7):607-12; http://dx.doi.org/10.1097/INF.0b013e3181d7d09c
   PubMed Web of Science ®Google Scholar
• Australian Public Assessment Report for Pneumococcal Polysaccharide Conjugate Vaccine (Prevenar 13®); [Internet]. Australian government department of health and ageing, therapeutic goods administration. 2011;; [cited 5 September 2013]. Available from http://www.tga.gov.au/pdf/auspar/auspar-pneumococcal-polysaccharide-conjugate-vaccine-13-valent
   Google Scholar
• Childhood Pneumococcal Immunisation Provider Guidelines Program providing a supplementary dose of the 13-valent pneumococcal vaccine (13vPCV); [Internet]. Australian government department of health immunise australia program. 2011;; [cited 10 October 2013] available from http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/pneumo-gsupp-cnt
   Google Scholar
• National immunisation program schedule Victoria July 2011. Department of Health, Victoria, Australia 2011;; [cited 2 June 2013] available from http://docs.health.vic.gov.au/docs/doc/National-Immunisation-Program-schedule-Victoria-July-2011
   Google Scholar
• Bryant K, Block SL, Baker SA, Gruber WC, Scott D. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Paediatrics 2010; 125 (5):866-75; http://dx.doi.org/10.1542/peds.2009-1405
   PubMed Web of Science ®Google Scholar
• Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, Jansen KU, Love J, Gruber WC, Emini EA, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Paediatrics 2010; 126(3) 493-505; http://dx.doi.org/10.1542/peds.2009-3027
   PubMed Web of Science ®Google Scholar
• Payton T, Girgenti D, Frenck RW, Patterson S, Love J, Razmpour A, Sidhu MS, Emini EA, Gruber WC, Scott DA. Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal vaccine given with routine pediatric vaccinations in the United States. Paediat Infect Dis J 2013; 32(8):871-80.
   PubMed Web of Science ®Google Scholar
• Khoie T, Tiernan R, deVore N. FDA briefing document Prevnar13 (PCV13) Vaccines and related biological products advisory committee; 2011; [cited 11 Oct 2013] available from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM279681.pdf
   Google Scholar
• Clothier HJ, Crawford NW, Kempe A, Buttery JP. Surveillance of adverse events following immunisation: the model of SAEFVIC Victoria. Commun Dis Intel 2011; 35(4):294-8
   PubMedGoogle Scholar
• Clothier HJ, Selvaraj G, McMinn A, Lewis G, Crawford NW, Buttery JP. SAEFVIC: Surveillance of adverse events following immunisation (AEFI) in Victoria, 2012. Victorian Infect Dis Bullet 2014; 17(1):2-9
   Google Scholar
• Definition and application of terms for vaccine pharmacovigilance. Reports of CIOMS\WHO Working Group on Vaccine Pharmacovigilance, Geneva, Council for International organizations of medical sciences, 2012. WHO 2012; [cited] available from http://www.cioms.ch/index.php/component/booklibrary/?task=view&Itemid=&id=45&catid=58
   Google Scholar
• Mahajan D, Cook J, Dey A, Macartney K, Menzies RI. Annual report: Surveillance of adverse events following immunisation in Australia, 2011. Commun Dis Intel 2012; 36(4):315-332.
   Google Scholar
• Mahajan D, Cook J, Dey A, Macartney K, Menzies R. Supplementary report: surveillance of adverse events following immunisation among children aged less than seven years in Australia, 1 January to 30 June 2012. Commun Dis Int 2013; 37(2):130-5.
   Google Scholar
• Weber JCP. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Adv Inflam Res 1984; 6:1-7
   Google Scholar
• Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy 2004; 24(6):743-9; PMID:15222664; http://dx.doi.org/10.1592/phco.24.8.743.36068
   PubMed Web of Science ®Google Scholar
• Centre KJ, Strauss A. Safety experience with heptavalent pneumococcal CRM197-conjugate vaccine (Prevenar) since vaccine introduction. Vaccine 2009; 27:3281-4; PMID:19200818; http://dx.doi.org/10.1016/j.vaccine.2009.01.060
   PubMed Web of Science ®Google Scholar
• Menzies R, Mahajan D, Gold MS, Roomiani I, McIntyre P, Lawrence G. Annual report: surveillance of adverse events following immunisation in Australia, 2008. Commun Dis Intel 2009; 33(4):365-81.
   Google Scholar
• Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM. Safety of human papilloma virus (HPV) vaccines: A review of the international experience so far. Vaccine 2009; 27(52):7270-81; PMID:19799849; http://dx.doi.org/10.1016/j.vaccine.2009.09.097
   PubMed Web of Science ®Google Scholar
• Lawrence G, Gold, MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intel 2008 32(4):371-87.
   Google Scholar
• Buttery JP, Madin S, Crawford NW. Mass psychogenic response to human papilloma-virus vaccination. Med J Australia 2008; 189:261-2; PMID:18759721
   PubMed Web of Science ®Google Scholar
• Horvath J. Review of the management of adverse events associated with Panvax and Fluvax 2011;; [cited 1 Nov 2013] available from http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/11DFBB4FD968D072CA25789400172DA1/$File/adverse-event-march-2011.pdf
   Google Scholar
• Tseng HF, Sy LS, Liu IA, Qian L, Marcy SM, Weintraub E, Yih K, Baxter R, Glanz JM, Donahue J, et al. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine 2013; 31:2578-258; PMID:23579258; http://dx.doi.org/10.1016/j.vaccine.2013.03.040
   PubMed Web of Science ®Google Scholar
• DuVernoy TS, Braun MM. Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996–1998. Paediatrics 2000; 106(4):E52; http://dx.doi.org/10.1542/peds.106.4.e52
   PubMed Web of Science ®Google Scholar
• Crawford NW, Clothier HJ, Hodgson K, Selvaraj G, Easton ML, Buttery JP. Active surveillance for adverse events following immunization. Expert Rev Vaccin 2014; 13(2):265-76; http://dx.doi.org/10.1586/14760584.2014.866895
   PubMed Web of Science ®Google Scholar
• Clothier HJ, Selvaraj G, Easton ML, Lewise G, Crawford NW, Buttery JP. Consumer reporting of adverse events following immunization. Hum Vaccin Immunot 2014; 10(12):3726-30; http://dx.doi.org/10.4161/hv.34369
   PubMed Web of Science ®Google Scholar
• Hull BP, Lawrence GL, MacIntyre CR, McIntyre PB. Immunisation coverage in Australia corrected for underreporting to the Australian Childhood Immunisation Register. Australian New Zealand J Public Health 2003; 27 (5):533-8; http://dx.doi.org/10.1111/j.1467-842X.2003.tb00829.x
   PubMed Web of Science ®Google Scholar
• Medical Dictionary for regulatory activities. MedDRA® trademark is owned by IFPMA on behalf of ICH; [cited 25 Oct 2012] available from http://www.meddra.org
   Google Scholar
• Causality assessment of an adverse event following immunization (AEFI): User manual for the revised WHO classification 2013. WHO 2013; [cited 12 April 2014] available from http://www.who.int/vaccine_safety/publications/aevi_manual.pdf?ua=1
   Google Scholar